Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPE and IVIG for Biological Age Rejuvenation
NCT06534450Phase 3Active, not recruiting
- Sponsor
- Dobri Kiprov
- Start
- Sep 2022
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of intravenous immunoglobulin G in aging (4 arms), sponsored by Dobri Kiprov. Primary endpoints: Adverse events and unanticipated events total for TPE safety at 1 year and Rate of change to blood epigenetic clock from TPE at 1 year. Started Sep 2022; status: active, not recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
aging
Beyond the preview
Go deeper on NCT06534450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534450.